Literature DB >> 2033430

The prognosis of Hodgkin's disease in older adults.

V F Guinee1, G G Giacco, M Durand, J W van den Blink, A Gustavsson, J G McVie, R Zewuster, S Dische, T Fahey, W Lane.   

Abstract

This investigation was undertaken to assess the apparent poor survival of older patients with Hodgkin's disease. The clinical course of Hodgkin's disease in 136 patients, 60 to 79 years of age, was compared with that of 223 patients, 40 to 59 years of age. The patients registered from November 1977 through December 1983 had not been previously treated, and were treated at eight cancer centers. When the prognosis of all patients was examined by age, a definite change in the pattern of survival first appeared in the 60- to 69-year-old cohort. The entire older group (60 to 79 years) experienced twice the risk of dying from Hodgkin's disease and four times the risk of dying from other causes than did the younger group. In both groups, stage of disease was the strongest factor in predicting adjusted survival. Delay in treatment and advanced stage at presentation were not characteristic of Hodgkin's disease in older patients as has been postulated. Older patients responded to therapy with a similar complete remission rate (84% v 88% in the younger group, P = .24). From this study, we conclude that (1) Hodgkin's disease in the older adult does not have a different natural history, its major risk factors are similar to those known in other age groups, and thus should be amenable to existing therapeutic approaches; and (2) the prognosis of older patients with Hodgkin's disease has been obscured in previous studies by the inclusion of deaths due to other causes in survival estimates.

Entities:  

Mesh:

Year:  1991        PMID: 2033430     DOI: 10.1200/JCO.1991.9.6.947

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

Review 1.  The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.

Authors:  Teresa V Halbsguth; Boris Böll; Peter Borchmann; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

2.  ABVD as the treatment option in advanced Hodgkin's lymphoma patients older than 45 years.

Authors:  Bosko M Andjelic; Biljana S Mihaljevic; Ljubomir R Jakovic
Journal:  Pathol Oncol Res       Date:  2012-01-11       Impact factor: 3.201

3.  Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.

Authors:  Ercole Brusamolino; Andrea Bacigalupo; Giovanni Barosi; Giampaolo Biti; Paolo G Gobbi; Alessandro Levis; Monia Marchetti; Armando Santoro; Pier Luigi Zinzani; Sante Tura
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

4.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

5.  Hodgkin's disease diagnosed post mortem: a population based study.

Authors:  H Hasle; A Mellemgaard
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

Review 6.  Hodgkin's Lymphoma in Older Patients: an Orphan Disease?

Authors:  Antoine Thyss; Esma Saada; Lauris Gastaud; Frédéric Peyrade; Daniel Re
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-07-01       Impact factor: 2.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.